| Literature DB >> 28053786 |
Mavidi Sunil Kumar1, Akanksha Singh2, Ashok Kumar Jaryal2, Piyush Ranjan1, K K Deepak2, Sanjay Sharma3, R Lakshmy4, R M Pandey5, Naval K Vikram1.
Abstract
Aim. The present study was designed to evaluate the heart rate variability (HRV) in nonalcoholic fatty liver disease (NAFLD) and to assess the effect of grade of NAFLD and diabetic status on HRV. Methods. This cross-sectional study included 75 subjects (25 NAFLD without diabetes, 25 NAFLD with diabetes, and 25 controls). Measurements included anthropometry, body composition analysis, estimation of plasma glucose, serum lipids, hsCRP, and serum insulin. HRV analysis was performed in both time and frequency domains. Results. The time and frequency domain indices of overall variability (SDNN, total power) were significantly lower in NAFLD with diabetes as compared to the controls. However, the LF : HF ratio did not differ among the three groups. The variables related to obesity, lipid profile, and glucose metabolism were also higher in NAFLD with diabetes and those with Grade II NAFLD without diabetes, as compared to controls. Multivariate stepwise regression analysis showed a negative correlation between HRV and total cholesterol and fat percentage. Conclusion. The grade of NAFLD as well as diabetic status contributes to the decrease in the cardiovascular autonomic function, with diabetic status rather than grade of NAFLD playing a critical role. Serum lipids and adiposity may also contribute to cardiac autonomic dysfunction.Entities:
Year: 2016 PMID: 28053786 PMCID: PMC5178370 DOI: 10.1155/2016/5160754
Source DB: PubMed Journal: Int J Hepatol
General, anthropometric, and biochemical parameters of the subjects.
| Controls | NAFLD without diabetes | NAFLD with diabetes |
| |
|---|---|---|---|---|
| Age (years) | 37.9 ± 8.4 | 41.8 ± 7.3 | 42.9 ± 7.6 | 0.04 |
| NAFLD Grades I, II, and III ( | — | 15, 10, 0 | 16, 8, 1 | 0.62 |
|
| ||||
| BMI (kg/m2) | 24.2 | 27.8 | 27.9 | 0.0001 |
| (21.7–26.6) | (24.8–31.2) | (25.7–30.1) | ||
| WHR | 0.95 ± 0.1 | 1.0 ± 0.1 | 1.0 ± 0.1 | 0.052 |
| Fat percentage (%) | 24.0 ± 6.7 | 26.6 ± 7.0 | 31.4 ± 6.2 | 0.001 |
| Fat mass (kg) | 15.4 ± 5.6 | 20.2 ± 7.5 | 21.7 ± 5.2 | 0.002 |
|
| ||||
| ESR (mm/hr) | 12.0 | 18.0 | 20.0 | 0.020 |
| (8.5–19.0) | (12.0–28.5) | (10.5–33.5) | ||
| hsCRP (mg/L) | 6.7 | 11.3 | 8.0 | 0.007 |
| (1.5–12.3) | (9.6–13.0) | (4.0–12.0) | ||
|
| ||||
| Bilirubin (mg/dL) | 0.6 | 0.5 | 0.5 | 0.916 |
| (0.4–0.8) | (0.4–0.8) | (0.3–0.8) | ||
| SGOT (AST) (IU/L) | 25.0 | 30.0 | 27.0 | 0.354 |
| (21.5–31.0) | (22.0–44.5) | (22.0–44.5) | ||
| SGPT (ALT) (IU/L) | 25.0 | 36.0 | 36.0 | 0.111 |
| (18.5–36.0) | (23.0–57.0) | (23.0–51.5) | ||
| ALP (IU/L) | 180.0 | 204.0 | 189.0 | 0.545 |
| (158.5–213.5) | (165.0–250.0) | (154.0–229.5) | ||
|
| ||||
| TG (mg/dL) | 132.0 | 140.0 | 161.0 | 0.228 |
| (81.0–173.5) | (98.5–222.0) | (115.5–201.5) | ||
| TC (mg/dL) | 168.0 | 191.0 | 218.0 | 0.005 |
| (144.0–196.5) | (162.5–235.5) | (171.5–230.0) | ||
| LDL (mg/dL) | 100.0 | 117.0 | 134.00 | 0.009 |
| (82.5–126.0) | (99.0–138.0) | (102.0–148.5) | ||
| HDL (mg/dL) | 44.0 | 45.0 | 46.0 | 0.423 |
| (40.5–49.5) | (40.5–47.5) | (41.0–53.5) | ||
| VLDL (mg/dL) | 20.0 | 30.0 | 32.0 | 0.003 |
| (16.0–26.5) | (19.5–42.0) | (23.5–43.5) | ||
|
| ||||
| FBG (mg/dL) | 89.0 | 97.0 | 118.0 | 0.0001 |
| (86.0–95.0) | (90.5–101.0) | (109.5–164.0) | ||
| PPBG (mg/dL) | 119.0 | 129.0 | 179.0 | 0.0001 |
| (104.0–128.0) | (118.5–142.0) | (154.5–218.5) | ||
| Fasting insulin ( | 10.5 | 15.6 | 11.4 | 0.323 |
| (5.9–17.2) | (5.4–20.7) | (10.0–17.2) | ||
| HOMA-IR | 2.0 | 3.8 | 3.8 | 0.0001 |
| (1.3–4.0) | (1.3–5.1) | (2.6–5.5) | ||
Values are expressed as median (IQR) or mean ± SD; significant versus control; #significant versus NAFLD without diabetes.
BMI: Body Mass Index; WHR: Waist Hip Ratio; ESR: Erythrocyte Sedimentation Rate; hsCRP: High-Sensitivity C Reactive Protein; SGOT: Serum Glutamic Oxaloacetic Transaminase; AST: Aspartate Transaminase; SGPT: Serum Glutamate Pyruvate Transaminase; ALT: Alanine Transaminase; ALP: Alkaline Phosphatase; IU: International Unit; TG: Triglycerides; TC: total cholesterol; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; VLDL: Very Low Density Lipoprotein; FBG: fasting blood glucose; PPBG: postprandial blood glucose; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance.
Time domain and frequency domain indices of HRV in the study population.
| Controls | NAFLD without diabetes | NAFLD with diabetes |
| |
|---|---|---|---|---|
|
| ||||
| SDNN (ms) | 40.7 | 30.2 | 22.2 | 0.006 |
| (24.6–61.5) | (15.5–47.8) | (17.59–28.2) | ||
| SDSD (ms) | 24.2 | 25.9 | 13.5 | 0.009 |
| (17.3–43.2) | (8.8–36.8) | (9.36–19.6) | ||
| pNN50 (%) | 0.04 | 0.04 | 0.00 | 0.008 |
| (0.00–0.22) | (0.00–0.16) | (0.00–0.01) | ||
|
| ||||
| LF nu | 40.2 | 41.9 | 37.8 | 0.855 |
| (33.4–53.6) | (27.1–52.3) | (23.9–53.2) | ||
| HF nu | 29.2 | 26.8 | 19.7 | 0.575 |
| (18.4–43.9) | (15.6–36.3) | (15.5–38.9) | ||
| LF : HF ratio | 1.5 | 1.6 | 1.6 | 0.843 |
| (1.0–2.6) | (1.0–2.2) | (0.9–2.9) | ||
| Total power (ms2) | 1166.5 | 658.4 | 310.6 | 0.005 |
| (383.5–2312.6) | (202.9–1379.2) | (173.3–545.4) | ||
Values are expressed as median (IQR); significant versus control; #significant versus NAFLD without diabetes.
SDNN: standard deviation of all NN intervals; SDSD: standard deviation of differences between adjacent NN intervals; pNN50%: NN50 count divided by the total number of all NN intervals; LF: low frequency (0.04–0.15 Hz); HF: high frequency (0.15–0.40 Hz); nu: normalized unit.
Time domain and frequency domain indices of HRV in controls, Grade I and Grade II NAFLD.
| Controls ( | Grade I ( | Grade II ( |
| |
|---|---|---|---|---|
| Diabetics ( | — | 16, 51.6% | 8, 44.4% | 0.62 |
|
| ||||
| SDNN (ms) | 40.7 | 28.3 | 21.2 | 0.010 |
| (24.6–61.5) | (19.5–46.3) | (14.7–26.0) | ||
| SDSD (ms) | 24.2 | 18.8 | 12.2 | 0.026 |
| (17.3–43.2) | (12.4–29.8) | (9.1–28.4) | ||
| pNN50 (%) | 0.04 | 0.01 | 0.00 | 0.016 |
| (0.00–0.22) | (0.00–0.07) | (0.00–0.01) | ||
|
| ||||
| LF nu | 40.2 | 37.8 | 44.5 | 0.435 |
| (33.4–53.6) | (27.1–53.3) | (20.1–50.0) | ||
| HF nu | 29.2 | 19.7 | 23.1 | 0.650 |
| (18.4–43.9) | (14.9–37.9) | (19.3–35.8) | ||
| LF : HF ratio | 1.5 | 1.6 | 1.4 | 0.804 |
| (0.9–3.0) | (0.9–3.4) | (0.8–2.7) | ||
| Total power (ms2) | 1166.5 | 515.0 | 255.1 | 0.006 |
| (383.5–2312.6) | (271.1–1374.3) | (157.5–382.6) |
Values are expressed as median (IQR); significant versus control.
SDNN: standard deviation of all NN intervals; SDSD: standard deviation of differences between adjacent NN intervals; pNN50%: NN50 count divided by the total number of all NN intervals; LF: low frequency (0.04–0.15 Hz); HF: high frequency (0.15–0.40 Hz); nu: normalized unit.
Two-way ANOVA for determination of main effect of diabetic status, NAFLD grade, and their interaction.
| Presence of diabetes | NAFLD grade | Interaction between diabetes and NAFLD grade | |
|---|---|---|---|
| SDNN | 0.054 | 0.140 | 0.461 |
| SDSD | 0.009 | 0.817 | 0.201 |
| Total power | 0.001 | 0.903 | 0.902 |
Significant.
Linear correlation analysis between the indices of HRV (dependent) and independent variables.
| SDNN | SDSD | Total power | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| Age (yr) | −0.242 | 0.046 | −0.301 | 0.013 | −0.212 | 0.083 |
|
| ||||||
| BMI (kg/m2) | −0.391 | 0.001 | −0.255 | 0.036 | −0.401 | 0.001 |
| WHR | −0.071 | 0.563 | 0.004 | 0.976 | −0.106 | 0.391 |
| Fat percentage (%) | −0.302 | 0.012 | −0.204 | 0.095 | −0.309 | 0.010 |
| Fat Mass (kg) | −0.319 | 0.008 | −0.220 | 0.071 | −0.333 | 0.006 |
|
| ||||||
| ESR (mm/hr) | −0.085 | 0.493 | −0.002 | 0.986 | −0.083 | 0.501 |
| hsCRP (mg/L) | −0.139 | 0.258 | −0.130 | 0.292 | −0.149 | 0.226 |
|
| ||||||
| Bilirubin (mg/dL) | −0.033 | 0.788 | −0.067 | 0.590 | −0.026 | 0.833 |
| SGOT (AST) (IU/L) | 0.117 | 0.344 | 0.137 | 0.265 | 0.062 | 0.615 |
| SGPT (ALT) (IU/L) | 0.007 | 0.955 | 0.035 | 0.779 | −0.041 | 0.739 |
| ALP (IU/L) | −0.137 | 0.266 | −0.103 | 0.405 | −0.137 | 0.266 |
|
| ||||||
| TG (mg/dL) | −0.240 | 0.048 | −0.178 | 0.147 | −0.281 | 0.020 |
| TC (mg/dL) | −0.405 | 0.001 | −0.301 | 0.013 | −0.390 | 0.001 |
| LDL (mg/dL) | −0.359 | 0.003 | −0.286 | 0.018 | −0.333 | 0.006 |
| HDL (mg/dL) | −0.081 | 0.512 | 0.001 | 0.995 | −0.051 | 0.678 |
| VLDL (mg/dL) | −0.368 | 0.002 | −0.270 | 0.026 | −0.401 | 0.001 |
|
| ||||||
| FBG (mg/dL) | −0.493 | 0.000 | −0.414 | 0.000 | −0.442 | 0.000 |
| PPBG (mg/dL) | −0.474 | 0.000 | −0.451 | 0.000 | −0.511 | 0.000 |
| Fasting insulin ( | −0.097 | 0.431 | −0.020 | 0.873 | −0.088 | 0.475 |
| HOMA-IR score | −0.225 | 0.065 | −0.150 | 0.223 | −0.200 | 0.102 |
Significant.
BMI: Body Mass Index; WHR: Waist Hip Ratio; ESR: Erythrocyte Sedimentation Rate; hsCRP: High-Sensitivity C Reactive Protein; SGOT: Serum Glutamic Oxaloacetic Transaminase; AST: Aspartate Transaminase; SGPT: Serum Glutamate Pyruvate Transaminase; ALT: Alanine Transaminase; ALP: Alkaline Phosphatase; IU: International Unit; TG: Triglycerides; TC: total cholesterol; LDL: Low Density Lipoprotein; HDL: High Density Lipoprotein; VLDL: Very Low Density Lipoprotein; FBG: fasting blood glucose; PPBG: postprandial blood glucose; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance.
Stepwise multivariate regression analysis of the indices of HRV with independent variables.
| SDNN | SDSD | Total power | ||||
|---|---|---|---|---|---|---|
| Beta |
| Beta |
| Beta |
| |
| Model 1 | ||||||
| TC | −0.482 | 0.0001 | −0.329 | 0.006 | −0.422 | 0.0001 |
| Model 2 | ||||||
| TC | −0.428 | 0.0001 | −0.369 | 0.001 | ||
| Fat% | −0.268 | 0.014 | −0.262 | 0.020 | ||
TC: total cholesterol.